But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good ...

Bayer's Monsanto has sued Pfizer, BioNTech and Moderna for allegedly misusing its messenger RNA technology in COVID vaccines.

The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual property developed by Monsanto, the crop science company the German company ...

Both the CEOs of Moderna and Pfizer said a booster dose of their respective COVID-19 vaccines could be required as soon as September for those who were among the earliest vaccinated. During an Axios ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

SAN FRANCISCO -- Herculean efforts by scientists and physicians around the world have resulted more than 50 experimental COVID-19 vaccines currently in global clinical trials. The focus in the U.S.

WASHINGTON, D.C. — U.S. health officials announced Wednesday that booster shots will soon be available to Americans who have received the COVID-19 vaccines made by Pfizer and Moderna. Officials with ...

Stream Connecticut News for free, 24/7, wherever you are. The new vaccines, which target the omicron variant XBB.1.5, are approved for people 12 and older and are authorized under emergency use for ...

A recent study suggests people may have protection from the coronavirus for years if they received the Pfizer-BioNTech or Moderna vaccine. The study was published in the journal Nature. “Overall, our ...

MOUNTAIN VIEW, Calif. -- It was the second shot California resident Veena Thomas had been for waiting for. Instead of relief what she felt was panic after the needle was pulled out. RELATED: Here's ...

Moderna’s 2028 cash breakeven guidance may not be feasible, analysts say.